NanoViricides Inc (NNVC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoViricides Inc (NNVC) has a cash flow conversion efficiency ratio of -0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($7.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NanoViricides Inc balance sheet quality to measure how much of total assets are equity-financed.
NanoViricides Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how NanoViricides Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can NanoViricides Inc service its debt to assess how comfortably operating cash covers total debt obligations.
NanoViricides Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoViricides Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QMINES LTD
F:81V
|
N/A |
|
NWP Holdings Bhd
KLSE:5025
|
-0.014x |
|
Sportshero Ltd
AU:SHO
|
1.185x |
|
Brooks Laboratories Limited
NSE:BROOKS
|
0.003x |
|
Caravelle International Group
NASDAQ:HTCO
|
-0.150x |
|
Zodiac Clothing Company Limited
NSE:ZODIACLOTH
|
-0.076x |
|
Agat Ejendomme A/S
CO:AGAT
|
0.005x |
|
BRAINCOOL AB
F:5YL
|
-0.135x |
Annual Cash Flow Conversion Efficiency for NanoViricides Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of NanoViricides Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see NanoViricides Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $7.52 Million | $-8.48 Million | -1.128x | -104.73% |
| 2024-06-30 | $11.46 Million | $-6.32 Million | -0.551x | -44.43% |
| 2023-06-30 | $14.87 Million | $-5.67 Million | -0.381x | -49.44% |
| 2022-06-30 | $23.08 Million | $-5.89 Million | -0.255x | +7.06% |
| 2021-06-30 | $29.91 Million | $-8.21 Million | -0.275x | +10.36% |
| 2020-06-30 | $21.76 Million | $-6.67 Million | -0.306x | +52.26% |
| 2019-06-30 | $10.60 Million | $-6.80 Million | -0.642x | -45.78% |
| 2018-06-30 | $17.66 Million | $-7.78 Million | -0.440x | -13.27% |
| 2017-06-30 | $20.32 Million | $-7.90 Million | -0.389x | -31.16% |
| 2016-06-30 | $23.05 Million | $-6.83 Million | -0.296x | -51.60% |
| 2015-06-30 | $31.79 Million | $-6.21 Million | -0.195x | +11.73% |
| 2014-06-30 | $28.60 Million | $-6.33 Million | -0.221x | +69.41% |
| 2013-06-30 | $8.01 Million | $-5.80 Million | -0.724x | -137.68% |
| 2012-06-30 | $13.85 Million | $-4.22 Million | -0.305x | +31.28% |
| 2011-06-30 | $10.17 Million | $-4.51 Million | -0.443x | -41.10% |
| 2010-06-30 | $6.52 Million | $-2.05 Million | -0.314x | +70.89% |
| 2009-06-30 | $2.49 Million | $-2.68 Million | -1.079x | +81.22% |
| 2008-06-30 | $443.74K | $-2.55 Million | -5.747x | -23.25% |
| 2007-06-30 | $500.34K | $-2.33 Million | -4.663x | -216.69% |
| 2006-06-30 | $1.24 Million | $-1.82 Million | -1.472x | -- |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more